EXITS Beyond Numbers: The Story of
Beyond Numbers: The Story of
Our Successful Investments
Sanitas
In 2003 together with business partners Baltvesta invested in Sanitas, generic pharmaceutical manufacturer. Subject to restructuring of management, good manufacturing practice (GMP) certificate and acquisition of companies in Slovakia and Poland, Sanitas grown about 10 times and became a significant player in the Central and Eastern
In 2011 Sanitas was sold to Valeant Pharmaceuticals International with EV 365M (13.1x EV/EBITDA multiple) at the exit.